Company* (Country; Symbol)
Amarillo Biosciences Inc. (OTC BB:AMAR)
Gesellschaft Fur Medizinisch and Technische Investionen mbH & CoKG (Germany)
Amarillo entered a deal with Curtis Martin, CEO of the German venture capital firm, for commercialization of low-dose oral interferon
GMTI will work to commercialize the product in Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia; terms were not disclosed (11/30)
A.P. Pharma Inc. (APPA)
Paul Royalty Fund
The fund purchased future royalties on sales of the dermatology products Retin-A Micro and Carac
A.P. Pharma received $25M up front, and could get $5M more if four-year targets are hit; A.P. was entitled to royalties through deals with Johnson & Johnson and Sanofi-Aventis companies (1/18)
ChondroGene Ltd. (Canada; CDNX:CDG)
Deal to develop a research database infrastructure for use in genomic research
The principal objective of the database is to standardize and achieve consistency in the format of data for future studies; terms were not disclosed (10/28)
Deal to integrate software for use in the drug discovery process
Terms of the deal were not disclosed; OmniViz focuses on visual informatics software (11/29)
* Private companies are indicated with an asterisk.
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market.
CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board.